血友病基因疗法达到3期临床终点 预计第三季度递交监管申请(2)
2019-08-13 未知 admin
[2] BioMarin Provides 3 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A. Retrieved May 28, 2019, from https://investors.biomarin.com/2019-05-28-BioMarin-Provides-3-Years-of-Clinical-Data-from-Ongoing-Phase-1-2-Study-of-Valoctocogene-Roxaparvovec-Gene-Therapay-for-Severe-Hemophilia-A
*声明:本文由入驻新浪医药新闻作者撰写,观点仅代表作者本人,不代表新浪医药新闻立场。▽关注【药明康德】微信公众号
鐑瘝锛